BlockchainFX Presale Nears $7.6M Milestone as 9,800+ Investors Jump In—While Pump.fun Shatters Records with $1B Daily Trading Frenzy

Crypto's retail revolution charges forward as BlockchainFX's presale momentum hits fever pitch—racking up $7.6M from a stampede of over 9,800 backers. Meanwhile, Pump.fun flexes serious muscle, notching a jaw-dropping $1B in daily trades as meme coin mania goes supernova.

Presale Power Play

BlockchainFX isn't just raising capital—it's building a army. With nearly ten thousand investors already locked in, this isn't a slow burn. It's a blaze.

Pump.fun's Billion-Dollar Day

One. Billion. Dollars. In one day. Let that sink in. While traditional finance gatekeepers scratch their heads, decentralized platforms are quietly eating their lunch—one trade at a time.

Retail's Revenge

This isn't institutional money moving markets. It's your neighbor, your barista, your cousin—all voting with their wallets while Wall Street still tries to figure out what a 'memecoin' even is.

Because nothing says 'financial innovation' like watching billion-dollar trades happen between cat-themed tokens and dog-inspired derivatives—while traditional brokers still charge $7 per trade.

Image source: Getty Images.

Weight loss in pill form

When injected, Wegovy doses generally run 1.7 mg or 2.4 mg in strength. In the oral study, Novo Nordisk administered once-a-day doses of Wegovy in pill FORM over 64 weeks -- at 25 mg.

And no, I didn't misplace a decimal there. When ingested instead of injected, much higher doses of semaglutide are required to get the same effect as in an injection, because so much of the ingested medicine is metabolized when passing through the liver before it can "do its job," so to speak.

Be that as it may, the higher dosages do clearly do their job. Indeed, 25 mg doses were found to help patients lose an average of 16.6% of their body weight over the course of the Novo Nordisk study. One patient in three managed to lose much more -- 20% of body weight.

Commenting on the results, Novo Nordisk chief scientific officer Martin Holst Lange pointed out that the weight loss numbers were comparable to what's achievable through injection -- no needles required.

Is Novo Nordisk stock a buy?

That's almost certain to make Wegovy more attractive to more potential consumers, boosting sales and profits for Novo Nordisk -- and it will need to. Priced at nearly 15x earnings now, paying less than a 3% dividend, and pegged for only an 8% growth rate over the next five years, Novo Nordisk stock is no longer the obvious bargain it once was.

More customer demand and a faster growth rate are exactly what Novo Nordisk needs to make this stock a buy again.